Mithun V Varghese, PhD Student
Inhalation drug delivery is one of the promising routes for ailments affecting lungs. Most of the inhalational devices such as nebulizer, pressurized multi dose inhaler (pMDI) and conventional Dry Powder Inhalers (DPI) are intended for drug deposition at the upper part of lung (i.e. bronchi and bronchioles). Due to environmental issues, Chlorofluorocarbon (CFC) propellant based pMDI technology is at the verge of retraction from the market. Researchers realized the potential DPI as a suitable replacement for pMDI. If twentieth century witnessed DPI formulations dedicated to asthma and chronic obstructive pulmonary disease (COPD), but recent launch of tobramycin DPI (TOBI podhaler) proved its ability in antibacterial therapy of cystic fibrosis. Approved excipients for DPI formulation are very limited because of the lower buffering capacity and its clearance from lung. My study includes synthesis of degradable and biocompatible lipid-polymer hybrids containing anti-TB drugs for targeting mycobacteria residing in the alveoli. We are trying to develop a carrier free strategy, through crystal engineering, for delivery of drugs to alveoli directly.